Hera BioLabs

INDIANAPOLIS, May 2, 2024 /PRNewswire/ -- 3CHI is proud to announce the successful conclusion of a detailed tolerability and safety assessment of its Platinum Delta 8 THC oil, conducted in collaboration with Hera Biolabs. This pivotal study further confirms the safety of Delta 8 THC and showcases 3CHI's continued pioneering scientific research within the cannabinoid sector. This is the first in a series of tests that 3CHI is conducting to evaluate and further prove the safety and efficacy of its products. Continue Reading In this detailed study, Sprague Dawley rats were administered various doses of 3CHI's 99% pure Platinum Delta 8 THC oil, with quantities adjusted to reflect human equivalents for an average 70 kg individual, ranging from 10 mg to 500 mg. Throughout the entire study, the rats displayed no significant adverse effects, thus confirming the product's safety at all administered doses. Importantly, the study also observed promising beneficial effects that will be explored in future clinical trials. 3CHI Demonstrates Safety and Potential Benefits of Delta 8 THC in Comprehensive Study Post this Justin Journay, CEO of 3CHI, stated, "This study bolsters the safety profile of our Delta 8 THC and illustrates that the criticisms leveled against delta 8 THC products and the broader hemp industry lack scientific basis and are primarily fueled by competitors' profit-driven motives—many of whom are now, hypocritically, selling hemp products." He further noted, "Marijuana companies and their affiliated testing labs are a primary source of much of the misinformation found in the hemp industry. They simply don't have the competency to keep up with the rapid scientific advancements of the hemp industry and have fallen back on fearmongering and demonstrably false prohibitionist tactics in order to protect falling market share." This study provides strong validation for the safety of 3CHI's Platinum Delta 8 THC oil, reinforcing its reliable safety profile even when used beyond recommended dosages. 3CHI continues to set the standard in the industry, emphasizing safety, transparency, and scientific integrity. Our proactive approach to research and unwavering commitment to quality set us apart in the dynamic cannabis market. For additional information or to learn more about 3CHI's dedication to continuous quality and innovation, please visit our website: . Contact: [email protected] SOURCE 3Chi

CHICAGO, July 21, 2023 /PRNewswire/ -- In the near future, the humanized mouse and rat model industry is set to undergo transformative advancements, revolutionizing biomedical research and drug development. These cutting-edge models, where mice and rats are genetically modified to possess human-like characteristics and immune systems, will play a pivotal role in bridging the gap between preclinical studies and clinical trials. Through refined genetic engineering techniques, these models will closely mimic human physiology, enabling more accurate and predictive assessments of drug safety, efficacy, and disease mechanisms. Moreover, the industry will witness the integration of advanced technologies, such as CRISPR/Cas9, to expedite the creation of customized humanized models, tailoring them to specific diseases or individual patient profiles. These advancements will spur collaboration between academia, pharmaceutical companies, and biotech firms, fostering a dynamic research ecosystem focused on targeted therapies and personalized medicine. Ultimately, the humanized mouse and rat model industry will emerge as a key driver in medical breakthroughs, enhancing our understanding of complex diseases and paving the way for transformative healthcare solutions. Humanized Mouse and Rat Model Market in terms of revenue was estimated to be worth $259 million in 2023 and is poised to reach $349 million by 2028, growing at a CAGR of 6.2% from 2023 to 2028 according to a new report by MarketsandMarkets™. Rising demand for personalized medicine is one of the prominent driving factor of the humanized mouse and rat model market. Existing mouse models have certain limitations in predictive research, unable to effectively gauge response in human cancer patients. Therefore, research institutes and academic institutes are focused on the development of advanced innovative models. Demand for personalized medicine is further driven by advancements in proteomics, genomics, and metabolomics. Additionally demand for targeted diagnostics and preventive medicine are propelling the demand for humanized mouse and rat research models. Download an Illustrative overview: Browse in-depth TOC on "Humanized Mouse and Rat Model Market" 140 - Tables 27 - Figures 188 - Pages Humanized Mouse and Rat Model Market Scope: The genetic models dominated the humanized mouse and rat model market in 2022. Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. The humanized mouse models segment is further divided into genetic humanized mouse models and cell-based humanized mouse models. The genetic models generated highest revenue in 2022. In genetic humanized mouse models, the human protein/domain is expressed while the mouse protein/domain is suppressed in all cells and tissues. Genetic humanized mouse models have been successfully adopted in analyzing biological efficacy, safety testing, pharmaceutical compounds, and studying novel therapeutics. Humanized mouse models are gaining demand in studies around drug metabolism and immune system development & functioning. The oncology segment represented a dominant share in the market in 2022. Based on application, the humanized mouse and rat model market is segmented into toxicology, oncology, immunology and infectious diseases, hematopoiesis, neuroscience, and other applications. Humanized models mimic human cancers and act as essential platforms for cancer research. Cancer research involves studying cancer biology and understanding or predicting cancer, including tumor characterization, tumorigenesis, and metastasis. The growth of this segment can be attributed to the growing number of cancer research programs in academic & research institutes and favorable support by governments for cancer research. The Asia Pacific region is the fastest-growing region of the humanized mouse and rat model market throughout the forecast period. Based on the region, the humanized mouse and rat model market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is estimated to register the highest growth during the forecast period. Increase in demand for market products across China and India is the key contributive factor. Led by growing R&D activities, the outsourcing of preclinical, clinical, and laboratory testing services for small & large molecules is expected to increase in the country. The growing pharmaceutical industry, the rising number of CROs, and rising research activities will drive the growth of China's humanized mouse and rat model market. Request Sample Pages: Humanized Mouse and Rat Model Market Dynamics: Drivers: Increasing research activities using humanized models Rising demand for personalized medicine Continuous support and initiatives from government and private sectors for cancer research Growing R&D activities in pharmaceutical and biotechnology sectors Restraints: High cost of custom humanized models Laws and regulations for ethical use of animal models in research Opportunities: Rising demand for humanized PDX models Emergence of CRISPR as a powerful tool in biomedical research Rising demand for humanized rat models Challenges: Alternatives for animal testing Limitations of humanized mouse models Key Market Players: The prominent players in the global humanized mouse and rat model market include Charles River Laboratories (US), THE JACKSON LABORATORY (JAX) (US), Taconic Biosciences, Inc. (US), Crown Biosciences (US), Champions Oncology, Inc. (US), Hera BioLabs (US), genOway (France), Inotiv (US), Vitalstar Biotechnology (China), Ingenious Targeting Laboratory (US), TRANS GENIC (Japan), Harbour Antibodies BV (Netherlands), Oncodesign (France), Pharmatest Services (Finland), Ozgene Pty Ltd. (Australia), TransCure services (France), Cyagen Biosciences (US), Aragen Life Sciences Ltd. (India), GemPharmatech (China), and Biocytogen (US). Recent Developments: In January 2022, Taconic Biosciences, Inc. (US) launched the huNOG-EXL EA (early access) humanized immune system (HIS) mouse. In October 2021, The Jackson Laboratory (US) acquired RMS Business of Charles River Laboratories Japan, Inc. (Japan) which is Charles River Laboratories Japan's Research Models & Services (RMS) business as a wholly-owned subsidiary. In September 2021, Biocytogen (US) collaborated with Envigo (US) in order to support the research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the US, Europe, and certain APAC regions. In March 2021, Charles River Laboratories International, Inc. (US) acquired Cognate BioServices, Inc. (US) a cell and gene therapy contract development and manufacturing organization (CDMO) offering comprehensive manufacturing solutions for cell therapies. The acquisition expanded Charles River's broad capabilities across the major CDMO platforms for cell and gene therapies. Get 10% Free Customization on this Report: Humanized Mouse and Rat Model Market Advantages: Predictive Validity: Humanized models closely mimic human physiology, genetics, and immune responses, providing a more accurate representation of human disease progression and treatment outcomes. This predictive validity enhances the reliability of preclinical data and improves the likelihood of successful translation to clinical trials. Reduced Ethical Concerns: Using humanized models reduces the need for animal testing on non-human species, addressing ethical concerns and promoting more humane research practices. Personalized Medicine: These models can be customized to replicate specific patient profiles or disease conditions, enabling personalized medicine approaches for tailored treatment strategies. Drug Efficacy and Safety Screening: Humanized models allow for rigorous assessment of drug efficacy and safety before progressing to human clinical trials, reducing the risk of adverse effects and optimizing the drug development process. Understanding Disease Mechanisms: By closely resembling human biology, these models offer valuable insights into disease mechanisms and underlying molecular pathways, advancing our understanding of complex diseases. Rapid and Cost-Effective Research: Humanized models can accelerate research timelines by providing faster results compared to traditional animal models. This efficiency reduces overall research costs and expedites the discovery of novel therapies. Translatability to Humans: The ability of humanized models to recapitulate human responses enhances the likelihood of successful translation of research findings to human patients, fostering more effective treatments. Targeted Therapies: Humanized models facilitate the evaluation of targeted therapies by replicating the specific molecular targets present in human diseases, aiding in the development of precision medicine approaches. Infectious Disease Research: Humanized models are particularly valuable in studying infectious diseases, allowing researchers to study pathogen-host interactions and test potential vaccines and antiviral treatments. Academic and Industry Collaboration: The widespread adoption of humanized models fosters collaboration between academic institutions, pharmaceutical companies, and biotech firms, encouraging a dynamic exchange of knowledge and resources to advance medical research collectively. Overall, the humanized mouse and rat model market represents a pivotal advancement in the biomedical field, enabling researchers to overcome the limitations of traditional models and paving the way for more effective and personalized medical interventions in the future. Related Reports: Mice Model Market - Global Forecasts to 2028 Life Science Instrumentation Market - Global Forecasts to 2028 CRO Services Market - Global Forecasts to 2028 Clinical Trial Supplies Market - Global Forecasts to 2027 Patient Derived Xenograft/PDX Model Market - Global Forecasts to 2026 About MarketsandMarkets™: MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit ™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected] Research Insight: Visit Our Website: Content Source: Logo: SOURCE MarketsandMarkets

CHICAGO, June 30, 2023 /PRNewswire/ -- In the near future, the CRISPR industry is poised to revolutionize various sectors with its unprecedented potential. The widespread adoption and advancements in CRISPR gene-editing technology have opened up new possibilities in healthcare, agriculture, and biotechnology. In healthcare, CRISPR is expected to play a crucial role in personalized medicine, allowing precise modifications to the human genome to treat genetic disorders and enhance disease prevention. Additionally, CRISPR-based diagnostics are likely to enable rapid and accurate detection of various pathogens and diseases. In agriculture, CRISPR holds immense promise for developing crops with enhanced traits, such as improved yield, disease resistance, and nutritional value, addressing global food security challenges. Moreover, the biotechnology industry is expected to leverage CRISPR for the development of novel therapies, biofuels, and industrial enzymes. As the CRISPR industry continues to expand, there will be a growing emphasis on ethical considerations, regulatory frameworks, and responsible use of this powerful technology to ensure its safe and equitable application for the benefit of humanity. CRISPR Market in terms of revenue was estimated to be worth $3.4 billion in 2023 and is poised to reach $7.1 billion by 2028, growing at a CAGR of 15.6% from 2023 to 2028 according to a new report by MarketsandMarkets™. Some of the prominent factors driving the growth of this market are technological advancements in the field of CRISPR, substantial support and funding for research and development in the CRISPR field from government and pharmaceutical companies are boosting the growth of the market. However, risk of off-target effects and safety concerns of CRISPR technology can hamper the market growth. Download an Illustrative overview: Browse in-depth TOC on "CRISPR Market" 39 - Tables 38 - Figures 170 - Pages CRISPR Market Scope: CRISPR products accounted for the largest share of the CRISPR market Among the products & services, the CRISPR market is segmented into CRISPR products, and CRISPR services. In 2023, the CRISPR products segment accounted for the largest share of the CRISPR market. Growth in this market segment can be attributed to prevalence of genetic disorders, such as inherited diseases and certain types of cancers, and the potential of CRISPR products to enhance the efficacy and precision of gene editing for therapeutic purposes. Drug Discovery & Development segment is the fastest-growing segment of the CRISPR market In 2023, the drug discovery & development segment accounted for the fastest-growing share of the application segment of CRISPR market. Market growth can largely be attributed to the potential of CRISPR technology to develop personalized therapies by precisely editing patient-specific genetic variations. The market is also driven by its application in drug target validation and lead optimization, increasing investment from both the public and private sectors, as well as CRISPR based functional genomics screening expediting the drug discovery process. Asia Pacific: The fastest-growing region in the CRISPR market The Asia Pacific CRISPR market is projected to grow at the highest CAGR during the forecast period, mainly due to increasing awareness of the importance of the research and development activities in the healthcare industry, large patient population, and advancements in sequencing technologies. The Asian market has also garnered significant attention from global players due to the increased focus on personalized medicine, driving the demand for CRISPR products. Request Sample Pages: CRISPR Market Dynamics: Drivers: Growing Investment and Funding from the Government for CRISPR Technology Restraints: High Technical challenges associated with CRISPR technology Opportunities: Development of new vaccine and treatment of genetic diseases Challenges: Regulatory Hurdles for CRISPR Advancements Key Market Players: The market for CRISPR is highly fragmented, with key players strategizing to capture the market. Prominent players in the CRISPR market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Genscript Biotech Corporation (China), CRISPR Therapeutics AG (Switzerland), Editas Medicine (US), Intellia Therapeutics, Inc. (US), Beam Therapeutics Inc. (US), Caribou Biosciences, Inc. (US), Lonza Group, Ltd. (Switzerland), Danaher Corporation (US), PerkinElmer, Inc. (US), Hera Biolabs (US), OriGene Technologies, Inc. (US), Cellecta, Inc. (US), Mammoth Biosciences, Inc. (US), Applied StemCell (US), New England Biolabs Inc. (US), ToolGen Inc. (South Korea), GeneCopoeia, Inc. (US), Twist Bioscience Corporation (US), Synthego Corporation (US), eGenesis (US), Inscripta, Inc. (US), and Precision BioSciences, Inc. (US). Recent Developments: In May 2023, Thermo Fisher Scientific opens cell therapy facility at UCSF to accelerate development of breakthrough therapies. Thermo Fisher Scientific Inc. and the University of California, San Francisco accelerated advanced cell therapies for difficult to treat conditions, including cancer, rare diseases, and other illnesses, from a newly opened cGMP manufacturing facility adjacent to UCSF Medical Center's Mission Bay campus. In April 2022, Thermo Fisher Scientific Inc. launched the new GMP-manufactured Gibco CTS TrueCut Cas9 Protein to support genome editing for research and manufacturing applications, including CAR T-cell therapy research. In November 2021, GenScript announced today that it has launched the GenWand Double-Stranded DNA (dsDNA) Service for the manufacture of CRISPR knock-in homology- directed repair (HDR) templates in T cell engineering. In October 2020, Merck announced that it signed agreements licensing its CRISPR technology to two companies PanCELLa, a cell therapy firm based in Toronto, Canada and Takara Bio USA, Inc., a biotechnology company based in Mountain View, California, USA. Get 10% Free Customization on this Report: CRISPR Market Advantages: Precision: CRISPR technology offers precise gene-editing capabilities, allowing for targeted modifications to specific genes or regions of the genome. This precision minimizes off-target effects and enhances the accuracy of gene editing, making it a powerful tool for therapeutic applications and research. Cost-effectiveness: Compared to traditional gene-editing methods, CRISPR is relatively cost-effective. The simplicity and efficiency of CRISPR systems reduce the time and resources required for experiments, making it more accessible to researchers and industries with limited budgets. Versatility: CRISPR has broad applications across various sectors, including healthcare, agriculture, and biotechnology. It can be used for gene therapy, developing diagnostic tools, creating genetically modified crops with improved traits, and engineering microorganisms for industrial purposes. This versatility expands the potential market for CRISPR-based products and services. Scalability: CRISPR technology can be scaled up for high-throughput applications, allowing for efficient editing of multiple genes or large-scale screening of genetic targets. This scalability is particularly beneficial for drug discovery, functional genomics, and other high-volume applications, driving its adoption in the pharmaceutical and biotech industries. Ongoing advancements: The field of CRISPR research and development is rapidly evolving, with continuous advancements and refinements being made to the technology. New variations and modifications of the CRISPR system, such as base editors and prime editors, further enhance its capabilities, expanding the range of potential applications and increasing its market advantage. Potential for personalized medicine: CRISPR has the potential to revolutionize personalized medicine by enabling targeted treatments for genetic disorders. The ability to edit specific genes associated with diseases offers new possibilities for developing tailored therapies, enhancing patient outcomes, and reducing healthcare costs. Ethical and regulatory considerations: Despite the advantages, the CRISPR market also faces ethical and regulatory challenges. Establishing robust ethical guidelines and regulatory frameworks will be crucial for responsible use and addressing potential concerns related to the technology's ethical implications and unintended consequences. Collaborative opportunities: The CRISPR market fosters collaboration between academia, industry, and research institutions. The technology's widespread adoption has led to partnerships and collaborations to leverage collective expertise and resources, driving innovation and accelerating the development of CRISPR-based products and services. Overall, the CRISPR market's advantages lie in its precision, cost-effectiveness, versatility, scalability, ongoing advancements, potential for personalized medicine, and collaborative opportunities, positioning it as a transformative force with significant market potential. CRISPR Market – Report Highlights: The value chain analysis, ecosystem analysis, and regulatory scenario are added in the market overview chapter. The new edition of the report provides updated market breakdown with detailed analysis on product & services, application and end user. The new edition of the report provides updated financial information till 2022 (depending on availability) for each listed company in a graphical representation. This would help in the easy analysis of the present status of profiled companies in terms of their financial strength, profitability, key revenue-generating region/country, and business segment focus in terms of the highest revenue-generating segment. Recent developments are helpful to understand market trends and growth strategies adopted by players in the market. Tracking product portfolios of prominent market players helps to analyze the major types in the CRISPR market. The new edition of the report provides an updated product portfolio of the companies profiled in the report. Market evaluation framework, market share analysis and competitive leadership mapping have been added in competitive landscape chapter of the report. The competitive leadership mapping has been updated considering recent developments in the company evaluation matrix. Related Reports: Genomics Market - Global Forecasts to 2028 Proteomics Market - Global Forecasts to 2028 NGS-based RNA-sequencing Market - Global Forecasts to 2027 Next Generation Sequencing Market - Global Forecasts to 2027 Genome Editing Market - Global Forecasts to 2026 About MarketsandMarkets™: MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit ™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected] Research Insight: Visit Our Website: Content Source: Logo: SOURCE MarketsandMarkets